


LISTING OF CLAIMS

Claims 1-18 (CANCELED)

19. (NEW) A compound selected from those of formula (I) :



wherein

- 5 • R₁ and R₂ each represent hydrogen or together form an additional bond,
- R₃ represents hydrogen or alkoxy,
- R₄ represents hydrogen or hydroxy, alkoxy, alkylcarbonyloxy or arylcarbonyloxy,
- R₅ represents hydrogen or halogen,
- R₆ represents hydrogen or alkyl, alkylcarbonyl or aroyl,
- 10 • R₇ represents alkoxy,
- R₈ and R₉ together form an additional bond,
- or R₈ and R₁₃ together form a sulphide bridge and, in that case, R₉ and R₁₀ together form
- oxo and R₁₄ represents chlorine,
- R₁₀ represents alkoxy,
- 15 • R₁₁ represents hydroxy or alkoxy,
- R₁₂ represents hydrogen,
- or R₁₁ and R₁₂ together form oxo, oxime or O-alkyl-oxime,
- and R₁₃ and R₁₄ each represent hydrogen or together form oxo,

with the proviso that the compound of formula (I) cannot represent :

- spiro[(4S,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one] (acutumine)
- 5 - spiro[(4S,5S)-4-acetyl-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one]
- spiro[(4S,5S)-4-acetyl-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-acetylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one]
- spiro[(4S,5S)-4-(benzoyloxy)-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one]
- 10 - spiro[(4S,5S)-4-hydroxy-cyclopentan-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-ol]
- spiro[(4S,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one]
- 15 - spiro[(4R,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one]
- spiro[(4S,5S)-4(benzoyloxy)-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1 benzoylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one]
- 20 - spiro[(4S,5S)-4-acetyl-cyclopentan-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one]
- spiro[4S,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1*H*-pyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one]
- 25 (acutumidine)
- spiro[4R,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1*H*-pyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one]
- spiro[(5S)-2-methoxy-2-cyclopenten-1-one-5:3-3aS,7aS-((2,3)-1*H*-pyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one]
- 30 - spiro[(5S)-2-methoxy-2-cyclopenten-1-one-5:3-2-chloro-3aS,7aS-((2,3)-1*H*-pyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],

it being understood that

- "alkyl" means an alkyl group containing 1 to 6 carbon atoms which may be linear or branched,
- "alkoxy" means an alkyloxy group containing 1 to 6 carbon atoms which may be linear or branched,
- "aryloxy" means an aryloxy group wherein the aryl moiety represents phenyl or naphthyl,
- "aroyl" means an arylcarbonyl group wherein the aryl moiety represents phenyl or naphthyl,

its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

20. (NEW) A compound according to Claim 19, wherein R_1 and R_2 , together form an additional bond, and R_8 and R_9 together form an additional bond.

21. (NEW) A compound according to Claim 19, wherein the groups R_3 , R_7 and R_{10} each represent methoxy.

22. (NEW) A compound according to Claim 19, wherein R_4 represents hydroxy, acetyloxy or benzoyloxy.

23. (NEW) A compound according to Claim 19, wherein R_5 represents chlorine.


24. (NEW) A compound according to Claim 19, wherein R_6 represents methyl or ethyl.

25. (NEW) A compound according to Claim 19, wherein R_6 represents hydrogen.

26. (NEW) A compound according to Claim 19, wherein R_{11} and R_{12} together form oxo.

27. (NEW) A compound according to Claim 19, wherein R_{13} and R_{14} each represent hydrogen.

28. (NEW) A compound according to Claim 19, wherein the compound has the configuration shown by formula (I') :



29. (NEW) A compound according to Claim 19, which is selected from

spiro[(4S,5S)-4-(ethoxycarbonyl)-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-
 5 ((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],

spiro[(4S,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-
 ethyl-pyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],

spiro[(4S,5S)-4-(ethoxycarbonyl)-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-
 ((2,3)-1-propanoylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],

10 spiro[(4S,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-
 methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one oxime],

spiro[(4S,5S)-3,4-dimethoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-
 methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],

15 spiro[(4R,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-
 methylpyrrolidine)-6,7-dimethoxy-2,3,3a,7a-tetrahydro-4*H*,5*H*-indene-4,5-dione],

spiro[(5S)-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methyl-
 pyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],

spiro[(4S,5S)-4-hydroxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-
 methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-ol],

20 spiro[(4R,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2,4-dichloro-3aS, and
 7aS-((2,3)-1-methylpyrrolidine)-7-methoxy-8-thiabicyclo[2.2.1]-1,2,3,3a,4,7a-hexahydro-5*H*,6*H*-
 indene-5,6-dione], its enantiomers, and addition salts thereof with a pharmaceutically
 acceptable acid or base.

30. (NEW) A method for treating a living animal body, including a human, afflicted with a condition selected from deficiencies of memory associated with cerebral ageing and with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 19 which is effective for alleviation of the condition.

31. (NEW) A pharmaceutical composition useful for the treatment of deficiencies of memory associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias comprising as active principle an effective amount of a compound of Claim 19 together with one or more pharmaceutically-acceptable excipients or vehicles.

32. (NEW) A method for treating a living animal body, including a human, afflicted with a condition selected from deficiencies of memory associated with cerebral ageing and with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias, comprising the step of administering to the living animal body, including a human, an amount of acutumine and/or an acutumine compound which is effective for alleviation of the condition.

33. (NEW) A method according to Claim 32, comprising the step of administering to the living animal body, including a human, an amount of acutumine which is effective for alleviation of the condition.

34. (NEW) A method according to Claim 32, comprising the step of administering to the living animal body, including a human, an amount of an acutumine compound which is effective for alleviation of the condition.

35. (NEW) A method according to Claim 32, wherein the acutumine compound is selected from:

spiro[(4S,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5H-inden-5-one] (acutumine),
spiro[(4S,5S)-4-acetyl-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5H-inden-5-one],

spiro[(4S,5S)-4-acetyl-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-acetylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],
 spiro[(4S,5S)-4-(benzoyloxy)-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],
 5 spiro[(4S,5S)-4-hydroxy-cyclopentan-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-ol],
 spiro[(4S,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],
 spiro[(4R,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],
 10 spiro[(4S,5S)-4(benzoyloxy)-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1benzoylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],
 spiro[(4S,5S)-4-acetyl-cyclopentan-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1-methylpyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],
 15 spiro[4S,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1*H*-pyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one] (acutumidine),
 spiro[4R,5S)-4-hydroxy-3-methoxy-2-cyclopenten-1-one-5:3(2S)-2-chloro-3aS,7aS-((2,3)-1*H*-pyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one],
 spiro[(5S)-2-methoxy-2-cyclopenten-1-one-5:3-3aS,7aS-((2,3)-1*H*-pyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one], and
 20 spiro [(5S)-2-methoxy-2-cyclopenten-1-one-5:3-2-chloro-3aS,7aS-((2,3)-1*H*-pyrrolidine)-6,7-dimethoxy-1,2,3,3a,4,7a-hexahydro-5*H*-inden-5-one].

36. (NEW) A pharmaceutical composition useful for the treatment of deficiencies of memory associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias comprising as active principle, an effective amount of acutumine or an acutumine compound, in combination with one or more pharmaceutically-acceptable excipients or vehicles.